WA IBM Interventions Summary October 2003 - September 2004

Date	Focus	# of Clients Targeted	# of Prescribers Targeted	Response Rate	Acceptance Rate	Estimated Monthly or 3 month Savings	Estimated Annual or 6 month Savings
	Preferred Long-Acting C-II Narcotics (Methadone			40	/	\$13,6182.27	\$1,225,640.46
October	and LA Morphine)	1015	527	43.55%	35.52%	(monthly)	(annual)
November	Preferred Long-Acting C-II Narcotics (Methadone and LA Morphine)	1003	616	33.90%	37.94%	\$78,181.10 (monthly)	\$703,629.90 (annual)
						\$4,084.03	\$36,756.27
December	PDL Estrogens	1004	400	53.09%	64.17%	(monthly)	(annual)
January	Drug-Disease Interaction-FDA Antidepressant Utilization/Link to Suicide Risk in Pediatric MDD	1034	471	n/a	n/a	n/a	n/a
February	PDL/Therapeutic Interchange Program Prescriber Education	1002	124	n/a	n/a	n/a	n/a
March	PDL/Therapeutic Interchange Program Prescriber INTERVENTION	1016	317	39.73%	31.31%	n/a	n/a
April	PDL/Therapeutic Interchange Program Prescriber INTERVENTION	1033	526	37.63%	28.19%	n/a	n/a
Мау	COX-2 Utilization INTERVENTION	1006	598	46.72%	22.13%	\$28,721.98 **Cumulative Savings 3 month post intervention	\$69,645.15 **Cumulative Savings 6 month post intervention
June	COX-2 Utilization INTERVENTION	1112	653	54.14%	19.10%	\$39,728.85 **Cumulative Savings 3 month post intervention	\$76,906.32 **Cumulative Savings 6 month post intervention
	COX-2 Utilization INTERVENTION	489	364	55.21%	21.96%	\$16,619.64 **Cumulative Savings 3 month post intervention	\$30,380.19 **Cumulative Savings 6 month post intervention
July	Preferred Long-Acting C-II Narcotics (Methadone and LA Morphine)	400	304	45.25%	18.23%	\$6,979.45 **Cumulative Savings 3 month post intervention	\$14,421.25 **Cumulative Savings 6 month post intervention
	Oxycontin > BID dosing INTERVENTION	128	117	50.78%	44.62%	\$15,213.85 **Cumulative Savings 3 month post intervention	_

I	Mental Health Medication Utilization in DD					ATTACHMENT 6-2	
	 INTERVENTION (AA-HbA1c for DD pts and MOSES for DD pts)	1006	406	24.62%	n/a	n/a	n/a
	Mental Health Medication Utilization in DD	1020	365	23.60%	n/a	n/a	n/a

Note:

^{*}Response rate = percentage of clients that prescribers have responded on.

^{*}Acceptance rate = percentage of clients where recommendation was accepted by prescriber

^{*}Annual cost savings = (Monthly savings x 12) x 0.75

^{*}Beginning May 2004 a new cost-savings template was implemented looking at cumulative savings 3 and 6 months post intervention